The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACRX Detailed Price Forecast - CNN Money||View ACRX Detailed Summary - Google Finance|
|View ACRX Detailed Summary - Yahoo! Finance||View ACRX Stock Research & Analysis - Zacks.com|
|View ACRX Trends & Analysis - Trade-Ideas||View ACRX Major Holders - Barrons|
|View ACRX Call Transcripts - NASDAQ||View ACRX Breaking News & Analysis - Seeking Alpha|
|View ACRX Annual Report - CompanySpotlight.com||View ACRX OTC Short Report - OTCShortReport.com|
|View ACRX Fundamentals - TradeKing||View ACRX SEC Filings - Bar Chart|
|View Historical Prices for ACRX - The WSJ||View Performance/Total Return for ACRX - Morningstar|
|View the Analyst Estimates for ACRX - MarketWatch||View the Earnings History for ACRX - CNBC|
|View the ACRX Earnings - StockMarketWatch||View ACRX Buy or Sell Recommendations - MacroAxis|
|View the ACRX Bullish Patterns - American Bulls||View ACRX Short Pain Metrics - ShortPainBot.com|
|View ACRX Stock Mentions - StockTwits||View ACRX Stock Mentions - PennyStockTweets|
|View ACRX Stock Mentions - Twitter||View ACRX Investment Forum News - Investor Hub|
|View ACRX Stock Mentions - Yahoo! Message Board||View ACRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACRX - SECform4.com||View Insider Transactions for ACRX - Insider Cow|
|View ACRX Major Holdings Summary - CNBC||View Insider Disclosure for ACRX - OTC Markets|
|View Insider Transactions for ACRX - Yahoo! Finance||View Institutional Holdings for ACRX - NASDAQ|
|View ACRX Stock Insight & Charts - FinViz.com||View ACRX Investment Charts - StockCharts.com|
|View ACRX Stock Overview & Charts - BarChart||View ACRX User Generated Charts - Trading View|
Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
Posted on Wednesday April 18, 2018
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) ("AcelRx").If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On April 16, 2018, the specialty pharmaceutical Company, which is focused on the development and commercialization of innovative therapies for the treatment of acute pain, declared the successful completion of the human factor study to validate the effectiveness of the revised DSUVIA directions for use (DFU).
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
Posted on Wednesday April 18, 2018
REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
Posted on Monday April 16, 2018
REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
Posted on Wednesday April 11, 2018
REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute pain in the emergency department (ED) in the peer-reviewed journal Drugs in Context. This manuscript reports on the results of a micro-costing analysis to estimate the burden of IV administration of morphine in five key European countries based on a literature review.